EVMN Evommune

• $70.2M bought by 6 insiders
• None no sales outside a trading plan
• $2.3M sold by 6 insiders under 10b5-1 plans

1. Insider
   Trade
   Value
   Traded, filed
2. Kyle Carver CFO
   Buy
   $13K 1,000 shares at $13.26 +1.7% to stake
   Traded Jul 8 Filed Jul 10
   ↗
3. Arthur S Kirsch Director
   Buy
   $133K 10,000 shares at $13.30 New stake
   Traded Jul 7 Filed Jul 8
   ↗
4. Jeegar Pravinkumar Patel Chief Scientific Officer
   Planned sale
   $33K 1,488 shares at $22.50 3.1% of stake
   Traded Jun 22 Filed Jun 24
   ↗
5. Janice Suzann Drew Chief of Dev. Operations
   Planned sale
   $453K 20,000 shares at $22.63 23% of stake
   Traded Jun 22 Filed Jun 24
   ↗
6. Luis C. Pena CEO
   Planned sale
   $169K 7,438 shares at $22.71 1.2% of stake
   Traded Jun 22 Filed Jun 24
   ↗
7. Jeegar Pravinkumar Patel Chief Scientific Officer
   Planned sale
   $379K 16,687 shares at $22.74 26% of stake
   Traded Jun 1 Filed Jun 3
   ↗
8. Luis C. Pena CEO
   Planned sale
   $382K 16,787 shares at $22.74 2.6% of stake
   Traded Jun 1 Filed Jun 3
   ↗
9. David E Cohen Director
   Planned sale
   $123K 6,056 shares at $20.33 26% of stake
   Traded Jun 2 Filed Jun 3
   ↗
10. Kyle Carver CFO
    Planned sale
    $415K 18,175 shares at $22.84 23% of stake
    Traded May 28 Filed Jun 1
    ↗
11. Gregory S. Moss Chief Business & Legal Officer
    Planned sale
    $325K 14,223 shares at $22.83 19% of stake
    Traded May 28 Filed Jun 1
    ↗
12. Robert Lorne Hopfner Director
    Buy
    $17K 1,000 shares at $17.35 +33% to stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
13. Weegen Felice Isabel Verduyn-van Director
    Buy
    $25M 1,562,500 shares at $16.00 +46% to stake
    Traded Nov 7, 2025 Filed Nov 12, 2025
    ↗
14. Ra Capital Management, L.P. Director
    Buy
    $20M 1,250,000 shares at $16.00 New stake
    Traded Nov 7, 2025 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 18 conversions, 6 share withholdings for taxes, 6 option exercises, and 4 stock grants.